In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece

Department of Microbiology, University Hospital of Larissa, Larissa, Greece.
International Journal of Antimicrobial Agents (Impact Factor: 4.3). 09/2008; 32(6):525-8. DOI: 10.1016/j.ijantimicag.2008.05.020
Source: PubMed


A total of 10420 Gram-positive cocci (including staphylococci, enterococci and various groups of streptococci) collected from clinically significant specimens in ten Greek hospitals during 2006--2007 were tested for their susceptibility to daptomycin. The minimum inhibitory concentration (MIC) was determined by the broth microdilution method. Daptomycin demonstrated very high activity against Enterococcus faecalis (MIC at which 50% of the isolates were inhibited (MIC50) = 1mg/L and MIC at which 90% of the isolates were inhibited (MIC90) = 1.36 mg/L), Enterococcus faecium (MIC50 = 1.36 mg/L and MIC90 = 1.90 mg/L), Streptococcus pyogenes (MIC50 = 0.12 mg/L and MIC90 = 0.50mg/L), Streptococcus agalactiae (MIC50 = 0.09 mg/L and MIC90 = 0.12 mg/L), Streptococcus pneumoniae (MIC50 = 0.24 mg/L and MIC90 = 0.5 mg/L) and viridans group streptococci (MIC50 = 0.50 mg/L and MIC90 = 0.89 mg/L). Resistance to linezolid and vancomycin for enterococci and to penicillin for streptococci appears to be independent of reduced susceptibility to daptomycin. On the other hand, daptomycin was also active against meticillin-resistant Staphylococcus aureus (MIC50 = 0.44 mg/L and MIC90 = 0.78 mg/L) and meticillin-resistant coagulase-negative staphylococci (MIC50 = 0.24 mg/L and MIC90 = 0.44 mg/L); however, 0.9% of the staphylococci tested had an MIC > 1mg/L, which is the Clinical and Laboratory Standards Institute breakpoint proposed for susceptibility. For all tested organism groups, resistance to daptomycin was not associated with glycopeptide resistance.

Download full-text


Available from: Efthymia Giannitsioti,
  • Source
    • "The programme also found quinupristin/dalfopristin to be inactive against 10% of E. faecium isolates.7 As expected, daptomycin activity against enterococci was not influenced by their susceptibility to ampicillin or quinupristin/dalfopristin.22,45 Furthermore, of 1000 E. faecium clinical isolates tested in Greece, 2.5% were resistant to linezolid and 15% were resistant to quinupristin/dalfopristin, but none was resistant to daptomycin. As in previous studies, there were no differences in daptomycin MICs for isolates that were resistant or susceptible to other antibiotics. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.
    Journal of Antimicrobial Chemotherapy 04/2010; 65(6):1126-36. DOI:10.1093/jac/dkq087 · 5.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A synthetic crystallic semihydrate form of calcium sulfate, Stimulan, was evaluated as a biodegradable carrier for the daily in vitro elution of daptomycin. Daptomycin and Stimulan were admixed at a ratio of 95:5. Elution lasted for 28 days. Eluted concentrations peaked on days 1 and 11, when the mean values were 1,320.1 and 949.2 μg/ml, respectively. The lowest eluted concentration was detected on day 28. These results support the application of the system described in experimental models of osteomyelitis.
    Antimicrobial Agents and Chemotherapy 05/2009; 53(7):3106-7. DOI:10.1128/AAC.01490-08 · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intravascular catheters are essential in most hospital units. These devices are the most common source of nosocomial bloodstream infections. Catheter-related bloodstream infections (CR-BSI) are associated with increased morbidity and mortality, prolonged hospitalization, and increased costs. CR-BSI can be diagnosed by different bacteriologic techniques, some of which can be performed in situ without withdrawing the device. Prevention strategies should aim to avoid extra- and endoluminal contamination. The management of CR-BSI includes catheter withdrawal and an appropriate antibiotic, which depends on the patient's clinical situation and on etiologic factors. Glycopeptide antibiotics are widely used for empirical treatment because of the high prevalence of staphylococcal infections. Antibiotic therapy should be reassessed when culture and sensitivity results are known.
    Expert Opinion on Pharmacotherapy 10/2009; 10(14):2231-43. DOI:10.1517/14656560903133819 · 3.53 Impact Factor
Show more